Top in ID: New Ebola treatment, COVID-19 vaccination recommendations
The FDA approval of a second Ebola treatment was the top story in infectious disease last week.
Recommendations from the CDC’s Advisory Committee on Immunization Practices for the next phase of COVID-19 vaccinations in the United States was another top story.
Read these and more of last week’s top stories in infectious disease below:
FDA approves another Ebola treatment
The FDA has approved Ebanga, a human monoclonal antibody developed by Ridgeback Biotherapeutics, for the treatment of Ebola virus. Read more.
Next phase of vaccinations should include patients over 75, essential workers, ACIP says
The next phase of COVID-19 vaccinations in the United States should include patients aged 75 years or older and frontline essential workers, including first responders, a CDC panel said on Dec. 20. Read more.
Online tool estimates effectiveness of COVID-19 pooled testing
An online tool utilizes SARS-CoV-2 data to aid policymakers in understanding the benefits of pooled testing in different populations, according to study results published in JAMA. Read more.
In shadow of COVID-19, TB vaccine research enters new era
In less than a year, scientists were able to develop several efficacious vaccines against COVID-19. Conversely, efforts to end tuberculosis have lagged and progress has stalled, according to experts, and WHO said that to meet End TB Strategy targets, a new vaccine is needed. Read more.
Cohort-based testing identifies inmates with asymptomatic, presymptomatic COVID-19
Early cohort-based testing among inmates helped identify new asymptomatic and presymptomatic COVID-19 cases that likely would have been missed by symptom screening, according to a study published in Clinical Infectious Diseases. Read more.